The FDA's removal of the partial clinical hold on Molecular Templates' Phase 1 clinical trial for MT-0169 is a positive development for the company. This allows the trial to proceed and focus on extramedullary myeloma, which could lead to potential revenue generation and increased investor confidence in the company's pipeline. As a result, the stock price may see a short-term positive impact.